• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对新冠肺炎患者的新兴治疗策略

Emerging Therapeutic Strategies for COVID-19 patients.

作者信息

Zhu Shudong, Guo Xialing, Geary Kyla, Zhang Dianzheng

机构信息

Argus Pharmaceuticals, Changsha, China.

Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA USA.

出版信息

Discoveries (Craiova). 2020 Mar 12;8(1):e105. doi: 10.15190/d.2020.2.

DOI:10.15190/d.2020.2
PMID:32309622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7093072/
Abstract

Over 100,000 cases of COVID-19 patients infected with the novel coronavirus SARS-COV-2 have been reported worldwide in approximately 2 months, resulting in over 3000 deaths. Potential therapeutic strategies, including remdesivir, chloroquine phosphate, abidol, lopinavir/ritonavir, plasma, antibody, vaccine and stem cells are discussed in this review. With the number of patients increasing daily, there is an urgent need for effective therapeutic intervention.

摘要

在大约两个月的时间里,全球已报告了超过10万例感染新型冠状病毒SARS-CoV-2的新冠肺炎患者,导致3000多人死亡。本综述讨论了潜在的治疗策略,包括瑞德西韦、磷酸氯喹、阿比多尔、洛匹那韦/利托那韦、血浆、抗体、疫苗和干细胞。随着患者数量每日增加,迫切需要有效的治疗干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/036c/7093072/390eeec6da2b/discoveries-08-105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/036c/7093072/390eeec6da2b/discoveries-08-105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/036c/7093072/390eeec6da2b/discoveries-08-105-g001.jpg

相似文献

1
Emerging Therapeutic Strategies for COVID-19 patients.针对新冠肺炎患者的新兴治疗策略
Discoveries (Craiova). 2020 Mar 12;8(1):e105. doi: 10.15190/d.2020.2.
2
Therapeutic Options for COVID-19: A Review.新型冠状病毒肺炎的治疗选择:综述
Cureus. 2020 Sep 16;12(9):e10480. doi: 10.7759/cureus.10480.
3
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程:从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
4
Potential benefits of combination of and Zn supplements to treat COVID-19.联合使用[具体物质]和锌补充剂治疗新冠肺炎的潜在益处。 (注:原文中“and”前缺少具体物质,翻译时补充了“[具体物质]”以符合完整句子的表达)
J Herb Med. 2020 Oct;23:100382. doi: 10.1016/j.hermed.2020.100382. Epub 2020 Jun 24.
5
COVID-19: A review of therapeutics under investigation.新型冠状病毒肺炎:正在研究的治疗方法综述
J Am Coll Emerg Physicians Open. 2020 Apr 19;1(3):231-237. doi: 10.1002/emp2.12081. eCollection 2020 Jun.

引用本文的文献

1
Monkeypox: a global health emergency.猴痘:全球卫生紧急事件。
Front Microbiol. 2023 Apr 26;14:1094794. doi: 10.3389/fmicb.2023.1094794. eCollection 2023.
2
Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study.表没食子儿茶素没食子酸酯和槲皮素与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突糖蛋白(S糖蛋白)的相互作用:计算机模拟研究
Biomedicines. 2022 Nov 29;10(12):3074. doi: 10.3390/biomedicines10123074.
3
Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children.

本文引用的文献

1
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.2019 年新型冠状病毒刺突蛋白在预融合构象的冷冻电镜结构
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.
2
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒(2019 - 新冠病毒)。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
3
First Case of 2019 Novel Coronavirus in the United States.
瑞德西韦:首个获美国食品药品监督管理局批准用于幼儿的抗新冠病毒治疗药物。
Discoveries (Craiova). 2022 Jun 30;10(2):e151. doi: 10.15190/d.2022.10. eCollection 2022 Apr-Jun.
4
Analysis of the Rate of Confirmed COVID-19 Cases in Seoul and Factors Affecting It Using Big Data Analysis.利用大数据分析首尔确诊 COVID-19 病例的比例及其影响因素分析。
Asia Pac J Public Health. 2022 Nov;34(8):824-831. doi: 10.1177/10105395221124435. Epub 2022 Sep 16.
5
Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.人源相同序列、透明质酸和羟甲香豆素——新型冠状病毒肺炎的新机制与治疗
Mol Biomed. 2022 May 20;3(1):15. doi: 10.1186/s43556-022-00077-0.
6
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19.关于新型冠状病毒肺炎发病机制、诊断、预防及治疗的免疫学观点
Mol Biomed. 2021;2(1):1. doi: 10.1186/s43556-020-00015-y. Epub 2021 Jan 20.
7
Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic.风湿性疾病患者对 COVID-19 大流行期间药物使用的态度。
Adv Rheumatol. 2021 Sep 3;61(1):55. doi: 10.1186/s42358-021-00211-6.
8
Retrospective analysis on the clinical characteristics of patients who were reinfected with the Corona Virus in 2019.2019年新型冠状病毒再次感染患者临床特征的回顾性分析。
Am J Transl Res. 2021 May 15;13(5):5505-5511. eCollection 2021.
9
First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization.首批获得美国食品药品监督管理局和欧洲药品管理局紧急使用授权的新冠疫苗。
Discoveries (Craiova). 2021 Mar 5;9(1):e122. doi: 10.15190/d.2021.1.
10
Applications of virtual and augmented reality in infectious disease epidemics with a focus on the COVID-19 outbreak.虚拟和增强现实在传染病流行中的应用,重点关注新冠疫情。
Inform Med Unlocked. 2021;24:100579. doi: 10.1016/j.imu.2021.100579. Epub 2021 Apr 27.
美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
4
A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).中东呼吸综合征冠状病毒(MERS-CoV)治疗药物的系统评价。
Travel Med Infect Dis. 2019 Jul-Aug;30:9-18. doi: 10.1016/j.tmaid.2019.06.012. Epub 2019 Jun 25.
5
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.小分子GS-5734对恒河猴体内埃博拉病毒的治疗效果。
Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2.
6
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.氯喹是一种有效的严重急性呼吸综合征冠状病毒感染和传播抑制剂。
Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69.